These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 36150309)
1. Current progress of nanomedicine for prostate cancer diagnosis and treatment. Zhao J; Zhang C; Wang W; Li C; Mu X; Hu K Biomed Pharmacother; 2022 Nov; 155():113714. PubMed ID: 36150309 [TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
3. The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers. Freitas LF; Ferreira AH; Thipe VC; Varca GHC; Lima CSA; Batista JGS; Riello FN; Nogueira K; Cruz CPC; Mendes GOA; Rodrigues AS; Sousa TS; Alves VM; Lugão AB Nanomaterials (Basel); 2021 Sep; 11(10):. PubMed ID: 34685018 [TBL] [Abstract][Full Text] [Related]
4. Unique roles of nanotechnology in medicine and cancer. Alam F; Naim M; Aziz M; Yadav N Indian J Cancer; 2014; 51(4):506-10. PubMed ID: 26842179 [TBL] [Abstract][Full Text] [Related]
5. Current advances in the application of nanomedicine in bladder cancer. Zhang C; Zhao J; Wang W; Geng H; Wang Y; Gao B Biomed Pharmacother; 2023 Jan; 157():114062. PubMed ID: 36469969 [TBL] [Abstract][Full Text] [Related]
6. Applications of Nanoparticles Probes for Prostate Cancer Imaging and Therapy. Gao T; Bi A; Yang S; Liu Y; Kong X; Zeng W Adv Exp Med Biol; 2018; 1096():99-115. PubMed ID: 30324350 [TBL] [Abstract][Full Text] [Related]
7. Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Calatayud DG; Neophytou S; Nicodemou E; Giuffrida SG; Ge H; Pascu SI Front Chem; 2022; 10():830133. PubMed ID: 35494646 [TBL] [Abstract][Full Text] [Related]
8. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598 [TBL] [Abstract][Full Text] [Related]
9. Liposomal nanomedicines in the treatment of prostate cancer. Kroon J; Metselaar JM; Storm G; van der Pluijm G Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226 [TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
11. Fararjeh AS; Liu YN Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727 [TBL] [Abstract][Full Text] [Related]
12. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882 [No Abstract] [Full Text] [Related]
13. CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting. Lu K; Li Z; Hu Q; Sun J; Chen M Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408983 [TBL] [Abstract][Full Text] [Related]
14. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer. Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572 [No Abstract] [Full Text] [Related]
15. Nanoformulations for Targeted Drug Delivery to Prostate Cancer: An Overview. Hema S; Thambiraj S; Shankaran DR J Nanosci Nanotechnol; 2018 Aug; 18(8):5171-5191. PubMed ID: 29458568 [TBL] [Abstract][Full Text] [Related]
16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
18. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER]. Nishizawa K; Hattahara K; Onishi H; Yoshida T Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081 [TBL] [Abstract][Full Text] [Related]
19. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736 [TBL] [Abstract][Full Text] [Related]
20. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. Chen Z; Chen N; Shen P; Gong J; Li X; Zhao T; Liao B; Liu L; Liu Z; Zhang X; Liu J; Peng Z; Chen X; Xu M; Gui H; Zhang P; Wei Q; Zhou Q; Zeng H Prostate; 2015 Sep; 75(12):1247-54. PubMed ID: 25917338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]